View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Analysis
September 24, 2021

Why has the WHO asked governments to delay Covid-19 booster jabs?

While booster shots will likely be needed long-term, the WHO has argued that first jabs for poorer nations should be prioritised.

By Michael Goodier

The UK became the latest country to start offering booster doses of Covid-19 vaccines last week, following similar moves across other European countries. That’s despite the World Health Organisation calling for a moratorium on boosters until the end of 2021.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Pharmaceutical Technology has found 35 countries that are currently offering third doses (for any reason), with a further 11 planning to start injections in the near future, including the US, which this week approved Pfizer and BioNTech’s Covid-19 vaccine as a booster shot for those aged 65 and above, those at high-risk of severe disease, and those with occupational risk of exposure to the virus.

In most cases the rollout of boosters has been so far confined to immunocompromised people. Some other countries like Jordan have offered them as a top up to China’s Sinovac vaccine, which has a lower efficacy against Covid-19 than alternatives such as Pfizer and Moderna’s shots.

Other countries, like the UK, Germany and France, are offering broader rollouts of boosters, including to the elderly population. That follows recent evidence from the UK that immunity wanes over time especially in older people, and figures from Israel showing that booster jabs are effective at reducing hospitalisations.

So if booster jabs will stop elderly people getting sick and dying, why doesn’t the WHO encourage them?

The main reason is that while these countries get efforts underway to put third vaccine doses in arms, lower-income nations, particularly in Africa, are still struggling to inject people with first doses. As of 15 September, only three doses had been delivered per every 100 people in low income countries, compared to 121 in high-income countries.

This affects everyone, as unvaccinated nations with high infections have greater risk of developing new variants.

Vaccine supply isn’t a zero sum game, and manufacturing capabilities will increase over time, enabling everyone to get the vaccines they need. However, at the current moment global supplies are limited.

Last week, COVAX (the scheme to provide vaccines to low and middle-income countries) slashed its forecasts for Covid-19 vaccine deliveries by around a quarter this year - citing India’s export ban as a particular concern.

So what can be done to help speed up the vaccine rollout? Firstly, India needs to remove restrictions on vaccine exports (the country is one of the world’s largest manufacturers of Astrazeneca and Novavax). This week it agreed to do so, starting in October.

Secondly, vaccine manufacturers ought to prioritise supplies to COVAX, allowing them to access doses they have already paid for faster than wealthier and more vaccinated nations such as the UK or US.

Western nations could be doing more to speed up manufacturing. This includes faster regulatory approval of manufacturing plants, of which China has plenty of spare yet unapproved capacity.

Booster jabs will eventually be necessary, but delaying the rollout – especially to those less at risk – could help free up some vaccine supplies for other countries in the here and now.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology